(VEEV) Veeva Systems - Overview
Sector: Healthcare | Industry: Health Information Services | Exchange: NYSE (USA) | Market Cap: 25.829m USD | Total Return: -33.4% in 12m
Avg Turnover: 337M
EPS Trend: 98.8%
Qual. Beats: 14
Rev. Trend: 99.9%
Qual. Beats: 9
Warnings
No concerns identified
Tailwinds
Confidence
Veeva Systems Inc. is a vertical software-as-a-service (SaaS) provider focused exclusively on the global life sciences industry. The company operates through two primary segments: Veeva Commercial Cloud, which facilitates customer relationship management and data analytics, and Veeva Vault, a unified platform for clinical, regulatory, and quality management. By centralizing these functions, Veeva helps pharmaceutical and biotechnology firms navigate complex compliance requirements while accelerating product development cycles.
The business model relies on a subscription-based revenue stream, which typically results in high customer retention rates due to the significant integration of its software into core R&D and commercial workflows. Unlike horizontal SaaS providers, Veeva’s specialized focus allows it to address the unique regulatory hurdles of the healthcare technology sector, such as maintaining data integrity for clinical trials. Investors looking for deeper insights into these industry-specific metrics may find further value in exploring the data on ValueRay.
Beyond software, the company provides professional services including system implementation, technical consulting, and managed services to support its global client base. Headquartered in Pleasanton, California, Veeva has expanded its footprint across North America, Europe, and Asia since its incorporation in 2007.
- Vault CRM migration creates near-term revenue headwinds during multi-year customer transition period
- R&D platform expansion drives high-margin subscription growth in Clinical and Quality segments
- Life sciences budget constraints impact professional services and consulting revenue growth rates
- Data Cloud adoption and Compass launch accelerate expansion into large-scale longitudinal analytics
| Net Income: 908.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.15 > 0.02 and ΔFCF/TA 0.90 > 1.0 |
| NWC/Revenue: 199.1% < 20% (prev 178.8%; Δ 20.28% < -1%) |
| CFO/TA 0.16 > 3% & CFO 1.42b > Net Income 908.9m |
| Net Debt (-6.46b) to EBITDA (954.3m): -6.77 < 3 |
| Current Ratio: 4.89 > 1.5 & < 3 |
| Outstanding Shares: last quarter (168.3m) vs 12m ago 1.56% < -2% |
| Gross Margin: 75.53% > 18% (prev 0.75%; Δ 7.48k% > 0.5%) |
| Asset Turnover: 39.16% > 50% (prev 37.42%; Δ 1.74% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
| A: 0.71 (Total Current Assets 8.00b - Total Current Liabilities 1.64b) / Total Assets 8.98b |
| B: 0.49 (Retained Earnings 4.36b / Total Assets 8.98b) |
| C: 0.11 (EBIT TTM 916.4m / Avg Total Assets 8.16b) |
| D: 2.48 (Book Value of Equity 4.37b / Total Liabilities 1.76b) |
| Altman-Z'' = 9.59 = AAA |
| DSRI: 1.07 (Receivables 1.31b/1.06b, Revenue 3.20b/2.75b) |
| GMI: 0.99 (GM 75.53% / 74.53%) |
| AQI: 0.75 (AQ_t 0.09 / AQ_t-1 0.12) |
| SGI: 1.16 (Revenue 3.20b / 2.75b) |
| TATA: -0.06 (NI 908.9m - CFO 1.42b) / TA 8.98b) |
| Beneish M = -3.07 (Cap -4..+1) = AA |
As of May 28, 2026, the stock is trading at USD 158.54 with a total of 1,906,047 shares traded.
Over the past week, the price has changed by -3.24%,
over one month by -1.19%,
over three months by -13.30% and
over the past year by -33.40%.
Veeva Systems has received a consensus analysts rating of 3.88. Therefore, it is recommended to buy VEEV.
- StrongBuy: 12
- Buy: 7
- Hold: 11
- Sell: 1
- StrongSell: 1
| Analysts Target Price | 262.7 | 65.7% |
P/E Trailing = 30.3199
P/E Forward = 17.8571
P/S = 8.0836
P/B = 3.5801
P/EG = 0.7306
Revenue TTM = 3.20b USD
EBIT TTM = 916.4m USD
EBITDA TTM = 954.3m USD
Long Term Debt = 83.7m USD (estimated: total debt 95.9m - short term 12.2m)
Short Term Debt = 12.2m USD (from shortTermDebt, last quarter)
Debt = 95.9m USD (from shortLongTermDebtTotal, last quarter) (leases 95.9m already included)
Net Debt = -6.46b USD (calculated: Debt 95.9m - CCE 6.56b)
Enterprise Value = 19.4b USD (25.8b + Debt 95.9m - CCE 6.56b)
Interest Coverage Ratio = unknown (Ebit TTM 916.4m / Interest Expense TTM 0.0)
EV/FCF = 13.93x (Enterprise Value 19.4b / FCF TTM 1.39b)
FCF Yield = 7.18% (FCF TTM 1.39b / Enterprise Value 19.4b)
FCF Margin = 43.49% (FCF TTM 1.39b / Revenue TTM 3.20b)
Net Margin = 28.44% (Net Income TTM 908.9m / Revenue TTM 3.20b)
Gross Margin = 75.53% ((Revenue TTM 3.20b - Cost of Revenue TTM 782.0m) / Revenue TTM)
Gross Margin QoQ = 74.46% (prev 75.41%)
Tobins Q-Ratio = 2.16 (Enterprise Value 19.4b / Total Assets 8.98b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 95.9m)
Taxrate = 23.09% (73.3m / 317.5m)
NOPAT = 704.7m (EBIT 916.4m * (1 - 23.09%))
Current Ratio = 4.89 (Total Current Assets 8.00b / Total Current Liabilities 1.64b)
Debt / Equity = 0.01 (Debt 95.9m / totalStockholderEquity, last quarter 7.21b)
Debt / EBITDA = -6.77 (Net Debt -6.46b / EBITDA 954.3m)
Debt / FCF = -4.65 (Net Debt -6.46b / FCF TTM 1.39b)
Total Stockholder Equity = 6.78b (last 4 quarters mean from totalStockholderEquity)
RoA = 11.14% (Net Income 908.9m / Total Assets 8.98b)
RoE = 13.41% (Net Income TTM 908.9m / Total Stockholder Equity 6.78b)
RoCE = 13.36% (EBIT 916.4m / Capital Employed (Equity 6.78b + L.T.Debt 83.7m))
RoIC = 9.63% (NOPAT 704.7m / Invested Capital 7.32b)
WACC = 7.95% (E(25.8b)/V(25.9b) * Re(7.98%) + D(95.9m)/V(25.9b) * Rd(0.0%) * (1-Tc(0.23)))
Discount Rate = 7.98% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 1.21%
[DCF] Terminal Value 77.97% ; FCFF base≈1.26b ; Y1≈1.45b ; Y5≈2.13b
[DCF] Fair Price = 235.9 (EV 32.0b - Net Debt -6.46b = Equity 38.5b / Shares 163.2m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 98.81 | EPS CAGR: 26.23% | SUE: 2.20 | # QB: 14
Revenue Correlation: 99.89 | Revenue CAGR: 15.32% | SUE: 3.01 | # QB: 9
EPS current Quarter (2026-07-31): EPS=2.19 | Chg30d=+0.00% | Revisions=+60% | Analysts=26
EPS current Year (2027-01-31): EPS=8.85 | Chg30d=+0.09% | Revisions=+81% | GrowthEPS=+9.3% | GrowthRev=+12.7%
EPS next Year (2028-01-31): EPS=9.88 | Chg30d=+0.00% | Revisions=-33% | GrowthEPS=+11.7% | GrowthRev=+12.2%
[Analyst] Revisions Ratio: +81%